Therapeutic flag Cosmetic cross-reference

Phloroglucinol

CAS 108-73-6

Phloroglucinol (CAS 108-73-6) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 266 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
4
SOURCE DrugCentral
Adverse signals
266
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Phloroglucinol
CAS Number
108-73-6
UNII
DHD7FFG6YS
InChIKey
QCDYQQDYXPDABM-UHFFFAOYSA-N
ChEMBL ID
CHEMBL473159
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural producttherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL473159 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Ki 8.815 nM 2 -
- IC50 36470 nM 1 -
- Potency 23778.1 nM 1 -
Beta-secretase 1
Enzyme
IC50 4.44 - Homo sapiens
SOURCE DrugCentral 40 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Hepatocellular injury 59 133.436 10019837
Drug reaction with eosinophilia and systemic symptoms 60 118.429 10073508
Febrile bone marrow aplasia 40 115.837 10053213
Pancreatitis acute 53 108.485 10033647
Acute kidney injury 132 102.295 10069339
Cholestasis 41 73.768 10008635
Urethral valves 13 73.327 10046479
Hyperleukocytosis 17 64.912 10078862
Thrombocytopenia 74 57.063 10043554
Toxic skin eruption 26 56.214 10057970
Cell death 17 55.289 10057248
Eosinophilia 32 53.765 10014950
Drug ineffective 8 49.679 10013709
Abdominal pain 82 47.586 10000081
Puncture site haematoma 8 46.495 10081957
Foetal exposure during pregnancy 40 44.382 10071404
Hyponatraemia 50 42.995 10021036
Wrong product administered 18 42.559 10081579
Fatigue 6 42.177 10016256
Hypokalaemia 45 41.889 10021015
Neutropenia 63 36.423 10029354
Hepatic cytolysis 20 34.466 10049199
Acute generalised exanthematous pustulosis 17 34.258 10048799
Septum pellucidum agenesis 6 34.015 10062267
Rash maculo-papular 26 33.991 10037868
Coma 34 33.613 10010071
Poisoning deliberate 17 33.374 10036000
Gamma-glutamyltransferase increased 26 33.112 10017693
Encephalopathy 27 31.292 10014625
Hepatosplenic candidiasis 7 31.051 10051590
Bicytopenia 11 30.95 10058956
Femoral artery aneurysm 6 30.541 10016427
Cardiac septal defect 8 30.428 10064021
Lung disorder 30 29.605 10025082
Prerenal failure 10 29.549 10072370
Porphyria 6 29.398 10036181
Electrocardiogram QT prolonged 30 29.053 10014387
Arteriovenous fistula 8 28.839 10003226
Respiratory distress 25 28.788 10038687
Benign soft tissue neoplasm 5 28.673 10061004

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Phloroglucinol used for in pharmaceutical contexts?

Phloroglucinol (CAS 108-73-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Phloroglucinol?

Phloroglucinol has 266 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Hepatocellular injury, Drug reaction with eosinophilia and systemic symptoms, Febrile bone marrow aplasia, Pancreatitis acute, Acute kidney injury. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Phloroglucinol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Phloroglucinol with EU status "permitted".

What clinical phase is Phloroglucinol in?

Phloroglucinol is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Phloroglucinol?

Phloroglucinol has 4 bioactivity rows in this page query. Rendered target entries include Beta-secretase 1.